Related Experiment Video

Updated: May 28, 2026

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia

G Christopher Wood1

  • 1The University of Tennessee Health Science Center College of Pharmacy, 881 Madison Avenue, Suite 205, Memphis, TN 38163, USA. cwood@uthsc.edu

Expert Review of Anti-Infective Therapy
|October 28, 2011
PubMed

Insights

Hospital-acquired pneumonia has poor cure rates with IV therapy alone. Aerosolized antibiotics, like aminoglycosides or colistin, may improve outcomes for resistant infections, but require careful administration to minimize adverse events.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Pharmacology

Background:

  • Hospital-acquired pneumonia (HAP) presents a significant clinical challenge with suboptimal treatment responses in certain patient populations.
  • Current intravenous antibiotic regimens for HAP may not achieve adequate lung tissue concentrations for effective eradication of pathogens.
  • Optimizing antibiotic delivery to the lungs is crucial for improving treatment efficacy in severe pneumonia cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of aerosolized antibiotics as an adjunct to intravenous therapy for hospital-acquired pneumonia.
  • To explore the potential of aerosolized aminoglycosides and colistin in treating multidrug-resistant organisms and nonresponding pneumonia.
  • To assess the feasibility of optimizing lung antibiotic concentrations through inhaled administration.

Main Methods:

  • Review of limited existing data on the use of aerosolized antibiotics (aminoglycosides, colistin) combined with intravenous therapy.
  • Analysis of response rates in patients with multidrug-resistant organisms or pneumonia unresponsive to conventional treatment.
  • Consideration of adverse events associated with aerosolized antibiotic administration, particularly with colistin.

Main Results:

  • Aerosolized antibiotics, when added to intravenous therapy, show promise for good response rates in specific pneumonia cases.
  • Positive outcomes are suggested in patients with multidrug-resistant pathogens or pneumonia refractory to standard treatment.
  • Potential for adverse events exists, with colistin requiring particular attention regarding safety.

Conclusions:

  • Aerosolized antibiotics represent a potentially valuable strategy for enhancing lung antibiotic concentrations in HAP.
  • This approach may improve outcomes for patients with difficult-to-treat or multidrug-resistant pneumonia.
  • Careful compounding and administration are essential to ensure tolerability and effective drug delivery, mitigating risks.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.